INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2014

Oral yeast-derived beta-glucans reduced upper respiratory infections in susceptible individuals and influenced various immune markers across studies.

This review evaluates the effects of orally administered yeast-derived beta-glucans (Y-BG). In human trials, Y-BG significantly reduced the incidence of upper respiratory tract infections in susceptible individuals, but not in healthy subjects, while altering markers such as salivary IgA, IL-10 in obese subjects, and monocytes in cancer patients. Studies evaluated doses ranging from 7.5 to 1500 mg/day across preparations varying in structure, molecular weight, and solubility. Animal studies also showed protective and antineoplastic enhancement effects.

Study type
Narrative review
Who was studied
Human trials (susceptible, healthy, obese, allergic, cancer subjects) and animal models
What was measured
Upper respiratory tract infections, immune markers, antineoplastic and protective effects

THE PAPER

Effects of orally administered yeast-derived beta-glucans: a review.

Samuelsen AB, Schrezenmeir J, Knutsen SH. Mol Nutr Food Res, 2014.

PubMed 24019098 ↗DOI 10.1002/mnfr.201300338 ↗

CancerNutrients & adequacyOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.